|
BioSignia is a predictive modeling company delivering
innovative solutions to the healthcare and life insurance
industries. BioSignia’s health risk assessment (HRA)
engine significantly improves prevention and management of
chronic diseases by focusing on individualized disease
risk assessment (DRA).
BioSignia’s cutting-edge underwriting technology enables
life insurance companies to attract and retain higher
value customers through more accurate mortality
assessment.
Through the use of its patented and proprietary
technologies the company has the largest suite of chronic
disease prediction models in the industry. These include:
coronary heart disease, stroke, type 2 diabetes, diabetes
complications, second heart attack, lung cancer/COPD,
prostate cancer, breast cancer, colon cancer, congestive
heart failure and others.
BioSignia’s programs provide turnkey,
evidence based platforms for physicians, employers, health
plans and insurance companies to assess, monitor, and
quantify disease and chronic care management.
|
